Frances Wood, MD
Interventional Cardiology · Winston Salem, NCNPI 1083814149
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (40.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Siemens Medical Solutions USA, Inc. accounts for 66.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $3,924 and has fallen 92.7% since, to $287 in 2025.
Across 118 payments — averaging $82.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$6K
- Corindus Inc.$620
- Abbott$595
- Abiomed$268
- Irhythm Technologies, Inc.$229
- Edwards Lifesciences$227
- plus $1K from 19 others
Across 63 payments — averaging $3317.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$149K
- Corindus Inc.$36K
- Abbott$22K
- Siemens Medical Solutions USA, Inc.$2K
What the payments were for
- Consulting fees$3,50036%
- Speaking & faculty fees$1,75018%
- Travel & lodging$5796%
- Food & beverage$3,92940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 21 | $6,445 |
| Corindus Inc. | 5 | $620 |
| Abbott | 26 | $595 |
| Abiomed | 2 | $268 |
| Irhythm Technologies, Inc. | 5 | $229 |
| Edwards Lifesciences | 2 | $227 |
| Heartflow, Inc. | 3 | $219 |
| Boston Scientific | 4 | $216 |
| AstraZeneca | 4 | $175 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $173 |
| Pfizer | 10 | $153 |
| Novartis | 6 | $114 |
| Novo Nordisk | 3 | $55 |
| Teleflex LLC | 1 | $50 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $33 |
| Johnson & Johnson | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Vifor Pharma, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
| Nuwellis, Inc. | 1 | $12 |
| Opsens Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CorPath Imaging System$3,630
- CorPath GRX$2,701
- Impella$268
- FFRct$148
- COMET$125
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$124
- FARXIGA$122
- AMPLATZER$105
- Edwards SAPIEN 3 Transcatheter Heart Valve$103
How this compares
$9,758 in reported general payments places this provider in the 65th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 157 | $170,332 |
| EntrestoSacubitril/Valsartan | 98 | $96,782 |
| Repatha SureclickEvolocumab | 99 | $71,427 |
| FarxigaDapagliflozin Propanediol | 64 | $47,844 |
| JardianceEmpagliflozin | 40 | $37,729 |
| BrilintaTicagrelor | 23 | $15,937 |
| Repatha SyringeEvolocumab | 13 | $15,178 |
| Ranolazine ErRanolazine | 100 | $11,610 |
| Metoprolol Succinate | 361 | $4,436 |
| Atorvastatin Calcium | 326 | $3,662 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 148 | $2,802 |
| Ezetimibe | 124 | $2,302 |
| Losartan Potassium | 190 | $1,852 |
| Amlodipine Besylate | 235 | $1,728 |
| Furosemide | 363 | $1,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $153 | $170,332157 claims |
| NovartisEntresto | $114 | $96,78298 claims |
| AstraZenecaFarxiga, Brilinta | $175 | $63,78287 claims |
| Boehringer IngelheimJardiance | $21 | $37,72940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Winston Salem
- David ZhaoWinston Salem$78K
- Samuel TurnerWinston Salem$60K
- Nizar NoureddineWinston Salem$22K
- Peter BelfordWinston Salem$14K
- Robert PreliWinston Salem$12K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
- Ronald UszenskiMooresville$495K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.